Chimeric Therapeutics: Final Results in Phase 1 Trial of CORE NK Platform
Filed with ASX · · 5 pages · English
• Chimeric is advancing development of its CORE NK Platform as a combination therapy in blood cancers and as chimeric antigen receptor (CAR) NK therapies in solid tumors • Webinar to be held at 11am AEDT today. Click here to register. Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce the results of th
Chimeric Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Chimeric Therapeutics
- Chimeric partners with Be the Match BioTherapies
- Successful completion of Institutional Entitlement Offer
- Entitlement Offer to raise approximately $18.1 million
- Encouraging data from 2nd dose cohort in CLTX CAR T trial
- Sponsored Research Agreement with University of Pennsylvania
Later from Chimeric Therapeutics
- Security Class Suspension from Quotation CHMO
- Completion of retail component of Entitlement Offer
- CDH17 CAR t preclinical data featured in Nature Cancer
- Security Class Reinstatement to Quotation CHMO
- Strategic manufacturing partnership with WuXi ATU
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics